OCTOPOD-Ph2a A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer
- Coordinator
- Theolytics Ltd, United Kingdom
- Runs
- 1 June 2026 to 31 May 2029
- Status
- Running
- EU funding
- €8.0m
- Total cost
- €8.0m
- Partners
- 5 organisations in 3 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101289129
What the project is doing
In the project's own words, from its summary on CORDIS.
Annually 87,894 EU citizens are diagnosed with ovarian cancer (OC), with >75% at an advanced stage and poor long-term outcomes (<25% 5-year survival). Standard-of-care first-line treatments combine cytoreductive surgery, platinum-based chemotherapies, and paclitaxel. Although initially effective, most patients relapse (>70% within 3-years) and become resistant to treatment. There are no effective treatments for platinum-resistant OC (PROC) and patients have a life expectancy of <12-months.
Therapeutic challenges result from the heterogeneous and immune-suppressed nature of the tumour microenvironment, and high volume of cancer-associated fibroblasts (CAFs), that create barriers to treatment and promote tumour survival mechanisms. THEO-260 is a next-generation oncolytic virus demonstrating:- world-first dual efficacy, targeting both patient CAF- and cancer- cells- high tumour selectivity (low toxicity)- strong TME modulation (immune cell infiltration) and adaptive immune responses- high systemic activity (intravenous delivery via standard-of-care practices and treatment of metastatic tumours)Currently in Phase-1 trials, THEO-260 is expected to deliver a game-changer in PROC treatment, tripling patient survival, improving quality-of-life, and doubling 5-year survival rates for advanced stage disease.
The project assembles a world class consortium, comprising one of Europe’s leading SME OV Biotechs and 4 centres of excellence in the fields of gynaecological cancer, immunotherapies, and translational research. Our goals are to:- complete a 20-patient multi-centre, open label Phase-2a trial to assess preliminary efficacy,- undertake comprehensive translational research to assess THEO-260's pharmacokinetic, pharmacodynamic, and immune behaviour, and- leverage our partnership and knowhow to consolidate OV clinical development capabilities and best-practice within Europe (increasing OV trial capacity and accelerating development).
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Theolytics Ltd | Oxford | United Kingdom | Coordinator |
| University Health Network | Toronto | Canada | Participant |
| Institut Catala D'oncologia | Hospitalet de Llobregat | Spain | Participant |
| Universidad De Navarra | Pamplona | Spain | Participant |
| Institute of Cancer Research: the Royal Cancer Hospital Lbg | London | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI